Alzheimer's drug gets FDA panel's backing, setting the stage for broader use
Source: AP
By MATTHEW PERRONE today
WASHINGTON (AP) Health advisers on Friday unanimously backed the full approval of a closely watched Alzheimers drug, a key step toward opening insurance coverage to U.S. seniors with early stages of the brain-robbing disease.
The drug, Leqembi, received conditional approval from the Food and Drug Administration in January based on early results suggesting it could slow Alzheimers progression by several months. The FDA now is reviewing more definitive results to decide whether the drug should receive the agencys full endorsement.
The decision carries extra significance because insurers have held off on paying for the infused treatment until it has full FDA approval.
The FDA panel of outside advisers voted 6-0 that a large company study confirmed the drugs benefits for patients with mild or early Alzheimers. The nonbinding vote amounts to a recommendation for full approval, and the FDA is scheduled to issue a final decision on the matter by July 6.
Read more: https://apnews.com/article/leqembi-alzheimers-drug-fda-f438cd0d1df98d1df0677a219cee6fa7

jmbar2
(7,367 posts)Estimated cost $26,000 year, which could potentially drive up Medicare costs significantly due to the number of seniors with the disease. Hopefully the government can do something to drive down these costs.
Not a huge leap, but every step forward offers hope.
leighbythesea2
(1,289 posts)I had a long conversation with someone whose father was in a trial for this drug, and got the drug they found out after. He had nearly zero decline in the 4 years. He was able to keep taking it after the trial, once it was revealed he had not been in placebo group. It was so encouraging to talk to her, bc my mom has Alzheimers. Shes past early stage, so could not take it now. But its heartening.
SunSeeker
(56,908 posts)I hope they can bring the price down.
SouthernDem4ever
(6,619 posts)How will we know if it really works?